Monday, April 21, 2014

In conversation with Tony Pullen

In conversation with Tony Pullen

April 1, 2014 by · Leave a Comment 

Tweet Tony Pullen is one of the deans of Canadian capital markets. His career in biotech traces its roots to 1985 as an advisor to Cangene, which merged with Emergent BioSolutions (NYSE:EBS) in February. He also was instrumental in raising the initial capital for MDS Health Ventures, which went on to become MDS Capital Corp., […]

Glickman swinging for the fence again in Isotechnika merger

Glickman swinging for the fence again in Isotechnika merger

February 19, 2013 by · Leave a Comment 

Tweet Richard Glickman is poised to hit another home run with the proposed merger of his closely-held Aurinia Pharmaceuticals and Isotechnika Pharma (TSX:ISA) to create a global nephrology leader. Dr. Glickman has a decades-long track record of successfully developing and selling pharmaceutical and biopharmaceutical companies. For example, in 2001, he co-founded Aspreva Pharmaceuticals which went […]

Paladin backs away from Afexa

Paladin backs away from Afexa

October 3, 2011 by · Leave a Comment 

Tweet Paladin Labs (TSX:PLB) will not take up any shares of Afexa Life Sciences (TSX:FXA) under its hostile takeover offer when the bid expires on Friday. A condition of Paladin’s latest offer was that Afexa not increase a breakup fee with friendly suitor Valeant Pharmaceuticals International (NYSE, TSX:VRX). Last week, the breakup fee was increased […]

Afexa recommends holders take no action on Paladin offer

Afexa recommends holders take no action on Paladin offer

September 29, 2011 by · Leave a Comment 

Tweet The board of Afexa Life Sciences (TSX:FXA) is recommending that shareholders take no action on an amended takeover offer from Paladin Labs (TSX:PLB) of either 81 cents a share in cash or 0.0217 of a Paladin share for each common share of Afexa. Afexa said the board’s decision reflects an announcement that Valeant Pharmaceuticals […]

Afexa to oppose lifting poison pill

Afexa to oppose lifting poison pill

September 22, 2011 by · Leave a Comment 

Tweet Afexa Life Sciences (TSX:FXA) will oppose an application on Friday by Paladin Labs (TSX:PLB) before the Alberta Securities Commission to cease trade Afexa’s shareholder rights plans. Earlier today, Paladin said it would enhance its unsolicited takeover offer for all and any of the outstanding shares of Afexa if two shareholder rights plans are waived […]

Afexa sees benefits in Valeant takeover

Afexa sees benefits in Valeant takeover

September 6, 2011 by · Leave a Comment 

Tweet After attracting a friendly all-cash takeover offer from Valeant Pharmaceuticals International (NYSE:VRX) to trump a hostile bid, Afexa Life Sciences (TSX:FXA) is enthused about the path forward with Valeant. “Through our discussions with Valeant, it became apparent that they are interested in all parts of our business, not only the Canadian COLD-FX business,” Afexa […]

Labopharm to be acquired by Paladin Labs

Labopharm to be acquired by Paladin Labs

August 17, 2011 by · Leave a Comment 

Tweet Labopharm (NASDAQ:DDSS; TSX:DDS) has accepted a takeover bid from Paladin Labs (TSX:PLB), which will make an offer for all of the common shares of Labopharm at a price of 28.57 cents a share in cash. The purchase price represents a premium of 57.4% over the volume-weighted average price of Labopharm’s shares of 18.15 cents for the 30 […]

Paladin bids $50 million for Afexa Life Sciences

Paladin bids $50 million for Afexa Life Sciences

August 10, 2011 by · Leave a Comment 

Tweet Paladin Labs (TSX:PLB) is making an offer to acquire any and all of the issued shares of Afexa Life Sciences (TSX:FXA) for 55 cents a share cash or a stock swap valued at about $50 million, assuming all shares of Afexa not already owned by Paladin are tendered. On July 15, Paladin said it […]

Paladin Labs acquires 5.37 million more Afexa shares

Paladin Labs acquires 5.37 million more Afexa shares

July 18, 2011 by · Leave a Comment 

Tweet Paladin Labs (TSX:PLB) has raised its interest in Afexa Life Sciences (TSX:FXA) to 15.4 million shares or just under 15%  through market purchases on the Toronto Stock Exchange Friday. The 5,374,500 additional common shares of Afexa were purchased for prices between 36 cents and 55 cents. Paladin said it is considering its options regarding […]

Somaxon and Paladin in Silenor collaboration

Somaxon and Paladin in Silenor collaboration

June 8, 2011 by · Leave a Comment 

Tweet Somaxon Pharmaceuticals (NASDAQ:SOMX) and Paladin Labs (TSX:PLB) have entered into an exclusive collaboration under which Paladin will commercialize Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa. Under the terms of accord, Somaxon will receive an up-front payment of $500,000 and Paladin will purchase 2,184,769 […]

Next Page »

Google+